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DOI 10.1016/j.ccr.2011.11.017Open access under CC BY license.SUMMARYThe hypoxia inducible transcription factors (HIFs) control many mediators of vascular response, including
both angiogenic factors and small molecules such as nitric oxide (NO). In studying how endothelial HIF
response itself affects metastasis, we found that loss of HIF-1a in endothelial cells reduces NO synthesis,
retards tumor cell migration through endothelial layers, and restricts tumor cell metastasis, and that loss
of HIF-2a has in each case the opposite effect. This results from differential regulation of NO homeostasis
that in turn regulates vascular endothelial growth factor expression in an NO-dependent feedback loop.
These opposing roles for the two HIF factors indicate that both they and endothelial cells regulate metastasis
as malignancy progresses.INTRODUCTION
There is a link between the metastatic process and oxygen
deprivation (Brizel et al., 1996; Rofstad et al., 2010; Voss et al.,
2011). Hypoxia itself triggers the induction of the hypoxia induc-
ible (HIF) transcription factors; these in turn are linked to changes
in the capacity of tumor cells to migrate, undergo epithelial to
mesenchymal transition, and to a number of other processes
intrinsic to metastasis (Chen et al., 2010; Haase, 2009; Liao
et al., 2007; Yang et al., 2008). Hypoxic response via HIF activa-
tion also includes expression of factors such as vascular endo-
thelial growth factor (VEGF), and inducible nitric oxide synthase
(iNOS) that are known to facilitate both angiogenesis and tumor
cell access to the circulatory system (Ambs et al., 1998; Claffey
et al., 1996; Shweiki et al., 1992; Ziche and Morbidelli, 2009).
The role of the tumor cell in metastasis has been widely
examined and discussed (Chambers et al., 2002; Gupta and
Massague´, 2006). Significant evidence exists to indicate that
migration of tumor cells during hematogenous metastasis is
accelerated by a HIF-driven response (Liao et al., 2007; LuSignificance
There is a central role for endothelial cells in the process of m
tumor cells in their migration toward other organs. Vascular
metastasis, and all involve hypoxic insult to the endothelium. Th
is complex, and can act to both promote and retard metastas
regulation of endothelial nitric oxide production via hypoxic re
52 Cancer Cell 21, 52–65, January 17, 2012 ª2012 Elsevier Inc.et al., 2010; Zhong et al., 1999). This response in the metastatic
cell may be driven in part by alterations in tumor oxygenation,
which also impacts the tumor endothelium, and it follows that
the hypoxic endothelial cell (EC), because of its location, could
act as a gatekeeper to metastatic cell intravasation.
As intravasatory processes are related to the hypoxia found
throughout many solid tumors, hypoxia is also tied to the extrav-
asation process, through the arrest of migrating tumor cells in
capillary beds. The resultant thrombus formation can also result
in local hypoxia and ischemia, and reemergence of a growing
tumor through a second endothelial barrier. Evidence to support
this model includes the clear relationship between thrombus
formation and metastatic success (Amirkhosravi et al., 2010;
Cliffton and Grossi, 1974; Ostrowski et al., 1986; Palumbo
et al., 2005; Saito et al., 1980).
Hypoxia has potent effects on regulation of nitric oxide (NO)
(Melillo et al., 1995; Olson and van der Vliet, 2011; Takeda
et al., 2010). NO can affect the overall vascular tension of tumor
vessels, and also has numerous other localized effects on
vascular function (Gunnett et al., 2005; Ignarro et al., 1987;etastasis: they represent a critical barrier to the passage of
damage, clotting, and ischemia are correlated with tumor
is study demonstrates that the endothelial cell HIF response
is, dependent on the HIF isoform expressed and the overall
sponse.
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NO synthesis in EC under normoxia is controlled primarily
by endothelial NO synthase (eNOS) (Fukumura et al., 2001).
However, hypoxic response induces NO chiefly via iNOS.
Intriguingly, some reports have indicated that iNOS itself can
positively regulate VEGF expression during tumorigenesis (Van
der Wall and Palmer, 2006; Wang et al., 2001).
We have recently shown that in inflammatory cells, NO
homeostasis is modulated by differential expression of the HIF
isoforms HIF-1 and HIF-2 (Takeda et al., 2010) via regulation
of two opposing uses of l-arginine: HIF-1a-induced expression
of iNOS, and HIF-2a induced expression of arginase 1 (ARG1),
which can remove l-arginine from NO synthetic pathways
and thus reduce NO levels. The primary aim of this study was
to investigate the effect of EC-specific deletion of HIF-1a or
HIF-2a on NO homeostasis and metastatic progression.
RESULTS
Loss of HIF-1a in Endothelial Cells Reduces
Metastatic Rate
To examine HIF function and endothelial hypoxic response in
metastasis, metastatic success was assayed in murine progres-
sive transgenic tumorigenesis, utilizing the MMTV-PyMT model
of mammary cancer (Lin et al., 2003). These mice, maintained
on a C57/Bl6 inbred background were crossed to mice carrying
a conditional deletion of HIF-1a (Ryan et al., 2000) and the
TIE2CRE transgenic strain (Kisanuki et al., 2001). The expression
of the cre recombinase driven by the Tie2 promoter causes
deletion in conditionally targeted endothelial cells and bone
marrow-derived cells (Constien et al., 2001). In these first exper-
iments, and in keeping with previously published results (Tang
et al., 2004), overall effects on primary tumor growth were only
moderate (Figure 1A); however, metastatic success was strongly
reduced. At 16 weeks of age, when lung metastatic foci first
become evident in this model, they are virtually absent in the
Tie2Cre+ HIF-1adf mice (Figure 1B, left). This reduction in
metastasis is also evident at the endpoint of the model, where
overall primary tumor burdens are similar in wild-type andmutant
animals (Figure 1A); but where there is still an75% reduction in
numbers of metastatic pulmonary foci (Figure 1B, right). At the
terminal stage in this model, there was no significant difference
in vascular density in the mutant mouse tumors relative to
wild-type animals vascular density (data not shown).
Bone marrow transplantations of wild-type (WT) marrow
were then introduced into control and mutant mice; this is
necessary to circumvent bone marrow expression of the cre
recombinase in Tie2+cre mice, and results in mice with a
deletion solely in endothelial cells (Tang et al., 2004). When
GFP-tagged Lewis lung carcinoma cells (LLC) were introduced
into mammary fat pads and allowed to grow for 3 weeks, the
size of the primary tumor in the different hosts was again iden-
tical as were vessel densities (data not shown), but the number
of pulmonary foci was significantly reduced (Figure 1C, left).
Further analysis of the number of circulating GFP-tagged tumor
cells in the bloodstream at the time of sacrifice indicated tumor
cells in the circulation were reduced by 50% in tumor-bearing
HIF-1a endothelial cell deletion mutants (Figure 1C, right). This
indicates that HIF-1a in the endothelium plays a significant rolein determining the number of intravasating tumor cells in this
model.
Migration of Tumor Cells through Primary
Endothelial Cell Layers Is Differentially
Controlled by HIF-1a and HIF-2a
To better understand the mechanisms underlying HIF control of
tumor cell migration in vivo, a tissue culture model of the move-
ment of tumor cells through an endothelial layer was utilized.
Primary murine lung endothelial cells were harvested from
conditionally targeted mice and treated with cre recombinase-
expressing or control adenovirus; they were then assayed for
deletion efficacy, and subsequently cultured on an 8 mm filter
insert. Labeled tumor cells were then introduced to the control
or nullizygous endothelial cell layers and exposed to normoxia
or hypoxia (1%O2) for 9 hr, after which tumor cells that migrated
through the endothelial cell layer were counted. As can be seen
in Figure 1D, hypoxia acts to accelerate the migration of tumor
cells through wild-type endothelial cells in this system. However,
this increased migration is very significantly reduced when
endothelial cells lack HIF-1a (Figure 1D). Conversely, endothelial
cells lacking HIF-2a (Gruber et al., 2007) exhibit the opposite
phenotype: there, migration of tumor cells through the mutant
endothelial layer is accelerated relative to wild-type cells under
both normoxic and hypoxic conditions.
Deletion of Both iNOS and VEGF Inhibits Tumor
Cell Migration through Endothelial Cell Layers
during Hypoxia
TwoHIF target genes known to producemediators of endothelial
cell permeability are the angiogenic factor vascular endothelial
growth factor-A, or VEGF-A, and the inducible NO synthase, or
iNOS (or NOS2). To determine whether loss of either gene in
endothelial cells affects themigration of tumor cells in this assay,
primary lung iNOS null endothelial cells from global deletion
animals, and VEGF-A conditional null (Gerber et al., 1999)
primary lung endothelial cells (the latter treated ex vivo with cre
recombinase-expressing virus, as above) were isolated. Loss
of both endothelial VEGF-A and iNOS restricts the hypoxia-
induced migration of tumor cells through the endothelial
monolayer (Figure 1E).
Differential Regulation of VEGF Is Influenced by iNOS
Expression during Hypoxia
As shown above, loss of either iNOS or VEGF in endothelial cells
inhibits transmigration of tumor cells in a cell culture assay. To
determine whether iNOS or VEGF is up- or downstream during
hypoxic signaling in endothelial cells, iNOS mRNA expression
was assayed in primary VEGF null endothelial cells during
hypoxia (Figure 2A); and similarly, VEGF-A expression was as-
sayed in iNOS null endothelial cells under the same conditions
(Figure 2B). Loss of VEGF in endothelial cells has no significant
effect on expression of iNOS in normoxia, but did affect hypoxic
induction of iNOS (Figure 2A). However, loss of iNOS in endothe-
lial cells suppresses VEGF expression in both normoxia and
hypoxia (Figure 2B), as does specific inhibition of iNOS with
1400W in WT EC (Figure 2C). To determine whether this effect
on VEGF expression in endothelial cells is NO-dependent, an
NO donor (DETANONOate) was added to cultures toCancer Cell 21, 52–65, January 17, 2012 ª2012 Elsevier Inc. 53
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Figure 1. HIF-1a Deletion in Endothelial Cells Leads to Reduction in Metastatic Incidence in Transgenic and Xenograft Models
(A) Effect of Tie2-driven deletion of HIF-1a on primary tumor growth in the spontaneous breast tumor model PyMT (HIF-1adf/Tie2Cre/PyMT) during different
stages during tumor development, at 16 and 18 weeks, and at endpoint (when one tumor reaches diameter of 1 cm).
(B) Effect of Tie2-driven deletion of HIF-1a on spontaneous breast tumor model PyMT (HIF-1adf/Tie2Cre/PyMT) tumor metastases at 16 wks of age (left panel),
and at endpoint (when one tumor reaches diameter of 1 cm, right panel).
(C) LLCGFP cells were implanted in cleared mammary pads of endothelial cell-specific deletion of HIF-1a (HIF-1a null) obtained by regeneratingWT bone marrow
into HIF-1adf/Tie2cre+ mice. Effect of endothelial HIF-1a deletion on frequency of lung metastasis 3 weeks after tumor cell implantation (left) and on blood
genomic GFP levels, a measure of relative abundance of circulating tumor cells (right); Data in (A–C) are average ± SEM.
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HIF Isoforms in Endothelium during Metastasisa concentration of 5 mM; this addition resulted in restored VEGF
expression under hypoxia in iNOS null cells (Figure 2D). This
demonstrates that the hypoxic induction of VEGF in endothelial
cells is regulated by iNOS-mediated production of NO.
Endothelial Cell Expression of VEGF Is Suppressed by an
iNOS-Specific Inhibitor in a Tissue-Specific Fashion
The inhibition of hypoxic induction of autocrine VEGF-A would
be expected to reduce hypoxic activation of the Flk-1 (VEGFR2)
receptor by phosphorylation, and this is indeed seen in iNOS
null primary endothelial cells (Figure 2E, left, and phosphor
imaging quantification, right). Immunoprecipitation of VEGFR2
from primary lung endothelial cells followed by detection of
phosphotyrosine demonstrates that the hypoxic activation of
VEGFR2 is significantly reduced in cells lacking iNOS.
VEGFR2 signaling is critical for the induction of tube forma-
tion in cultured endothelium (Zhang et al., 2010). To determine
whether endothelial cell iNOS expression also affects this
VEGF-A-dependent phenomenon, cultured EC were placed
on collagen matrices, and as shown in Figure 2F, loss of EC
iNOS reduced tube formation 90%. Inhibition of iNOS protein
activity by the iNOS-specific inhibitor 1400W (30 mM) also
reduced tube formation significantly. These results indicate
that iNOS is a critical determinant of function in endothelial cells
in isolation.
Gene Expression Analysis of Hypoxic Endothelial Cells
It was recently shown that loss of HIF-1a and HIF-2a in macro-
phages has differential effects on the regulation of NO produc-
tion; loss of HIF-1a resulting in decreased iNOS expression
and decreased NO levels, and loss of HIF-2a in decreased
ARG1 expression and increased NO availability (Takeda et al.,
2010). Examination of normoxic expression of iNOS and ARG1
in WT, HIF-1a, and HIF-2a null endothelial cells reveals that
the two HIF-a factors also regulate iNOS and ARG1 differentially
in these cells. Loss of either HIF-1a or HIF-2a reduced the
expression of both iNOS and VEGF during hypoxia (Figure 3A);
however, only the loss of HIF-2a significantly reduced the
expression of Arginase1.
Hypoxic Induction of NO in Endothelial Cells Is HIF-1a
and iNOS Dependent
A number of studies have determined that under normoxic
circumstances, the primary factor in normoxic endothelial NO
production is the endothelial NO synthase (eNOS) (Fukumura
et al., 2001); however, eNOS is neither a HIF target nor a hy-
poxically responsive gene. To determine the role of iNOS in
endothelial cell hypoxia-induced NO production, assays for
NO metabolites were carried out on conditioned medium
from normoxic or hypoxic endothelial cells. There is a significant
increase in NO metabolites in hypoxically conditioned media,
and this is dependent on HIF-1a (Figure 3B). HIF-2a loss
causes an increase in NO metabolites under normoxic condi-
tions when compared to wild-type cells.(D and E) Boyden assay for tumor cell migration during 9h periods of normoxia (2
and HIF-2a null cells (D) and VEGF null and iNOS null cells (E). Data in (D) and (E
the mean number of migrated cells throughWT endothelium during normoxic con
p < 0.05; **p < 0.01; ***p < 0.001. NS indicates differences that do not reach a pInhibition of VEGF Expression by Suppression of iNOS
Is Specific to Endothelial Cells
To determine the endothelial specificity of the effects described
above, primary lung murine endothelial cells (mEC), human
umbilical vein endothelial cells (hUVEC), murine embryonic fibro-
blasts (mEF), and Lewis lung carcinoma cells (LLC) were treated
with the iNOS inhibitor 1400W (Figure 4A). Hypoxically-induced
VEGF expression was suppressed in both endothelial cell
cultures (mEC and hUVEC) treated with 1400W; however, there
was no suppression of VEGF mRNA by 1400W in the fibroblast
(mEF) or carcinoma (LLC) lines (Figure 4A). Another hypoxia-
induced HIF target, the glycolytic enzyme phosphoglycerate
kinase (PGK), is not as strongly affected by suppression of
iNOS in any of the cell types examined (Figure 4A). This indicates
that the suppression of VEGF expression through inhibition of
iNOS may not simply affect HIF-1a induction, but rather act
through a more complex mechanism.
Inhibition of iNOS Reduces Tumor VEGF Expression
In Vivo, but Does Not Significantly Affect Expression
of Other HIF Target Genes
LLC xenograft tumors were assayed for net effects on gene
expression when iNOS inhibitor was delivered at late stages of
tumor growth. After 14 days of subcutaneous tumor expansion
in wild-type animals, tumor-bearing mice received two injections
with either a saline control or 1400W intraperitoneally. Four
hours after the last injection, animals were sacrificed and
tumors removed; the injection with 1400W caused a significant
reduction in VEGF mRNA in the treated animals (Figure 4B).
No statistically significant effect was seen in any of the other
HIF targets assayed, including the two glycolytic enzymes
lactate dehydrogenase (LDH) and PGK. This indicates that
suppression of iNOS could be a useful modality for specifically
suppressing VEGF expression in tumors, where it presumably
acts at least in part on endothelial expression of the angiogenic
factor.
Differential Tumor Cell Migration through Endothelial
Cells Is Both HIF Isoform- and NO-Dependent
To determine whether iNOS is the critical factor that modulates
differential tumor cell migration through endothelial cells, tumor
cell migration was scored in endothelial layers treated with
either vehicle or 15 mM 1400W for 3 hr prior to tumor cell seed-
ing. Inhibitor and vehicle were removed and endothelial cells
were washed immediately prior to tumor cell introduction, in
order to limit the effects of the inhibitor compound solely to
the endothelial cells (Figure 5A). 1400W strongly suppressed
hypoxia-induced tumor cell migration through WT endothelial
cells; however, it had no suppressive effect on HIF-1a and
VEGF null endothelial cells. Suppression with 1400W had the
strongest effect on HIF-2a null endothelial cell layers, where
the degree of suppression indicates that altered NO levels
are likely a primary cause of elevated tumor cell migration in
this genotype.1% O2) or hypoxia (1% O2) through endothelial monolayers ofWT, HIF-1a null,
) are average ± SD of ratio of cells migrated through endothelium divided by
ditions. An asterisk is placed above differences with a significance exceeding
< 0.05 level of significance.
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Figure 2. Deletion and Specific Inhibition of iNOS Result in Decreased VEGF Expression and Downstream Activity
(A–C) Quantification of relative abundance of iNOSmRNA in VEGF null endothelial cells (A) and VEGFmRNA abundance in iNOS KO cells (B) orWT cells treated
with 15 mM of specific iNOS inhibitor 1400W (right panel) by quantitative RT-PCR (C).
(D) VEGF mRNA levels in WT and iNOS null endothelial cells upon addition of 5 mM NO donor DETA NONOate (dNO).
(E) Representative western blot of immunoprecipitated VEGFR2 (Flk1) probed for total Flk1 and P-tyrosine to detect activated form (left) and signal quantification
of multiple blots (n = 3) by phosphor imaging (right).
(F) Tube formation assay in collagen I matrix, representative pictures ofWT,WT + 30 mM1400W, and iNOS null are shown (left) (scale bar represents 100 mm) and
quantification of length of detected networks (right) was performed using ImageJ. Data is average ± SEMof lengths obtained from at least three pictures of at least
three wells. Experiment shown is representative and was repeated three times with cells no older than passage 2. In this figure, data shown is average ± SEM,
An asterisk is placed above differences with a significance exceeding p < 0.05; **p < 0.01; ***p < 0.001.
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Figure 3. Endothelial Cells Generate NO through iNOS
Activation during Hypoxia
(A) Relative abundance of iNOS and ARG1 transcripts in WT
(left), HIF-1a null (center), and HIF-2a null (right) endothelial
cells exposed to 21% O2 (normoxia) or 1% O2 (hypoxia) for
9 hr. Data is average ± SEM of each sample; mRNA levels are
compared to those observed in WT normoxia (that was
defined as 1.0-fold).
(B) NO levels in endothelial cell conditioned medium from cells
treated for 48 hr at 21% or 0.5% O2; data presented are
average ± SEM. An asterisk is placed above differences with
a significance exceeding p < 0.05; **p < 0.01; ***p < 0.001.
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that, as expected, iNOS deletion results in reduced endothelial
permeability to tumor cells (Figure 5B). A number of groups
have shown that inhibition or deletion of inducible NOS results
in suppression of tumor growth and metastasis (Ohtsu et al.,
2010; Thomsen et al., 1997); we also found that treatmentCancer Cewith 1400W prior to intravenous injection of 1 3
106 LLC cells causes a significant reduction in
metastatic success in vivo (Figure 5C).
Differential Migration and NO Regulation
Correlate with Metastatic Success in
EC-Specific HIF Isoform Null Mice
As shown above, the loss of HIF-1a in endothelial
cells reduces metastasis in mouse tumor models,
and reduces tumor cell migration through an
endothelial layer under hypoxia. The loss of
HIF-2a in endothelium accelerates tumor cell
migration in an NO-dependent manner. It was
thus important to determine whether these obser-
vations on the role of the different isoforms in
cultured endothelial cells is correlated with meta-
static success in vivo.
To model effects of this mutation on seeding of
cells into the pulmonary endothelium and tumor
cell extravasation, seeding of tumor cells into the
tail vein in WT, HIF-1a EC null animals, and
HIF-2a EC null animals was carried out. The
mutant mice were created by WT bone marrow
transplant into Tie2cre/conditional allele animals,
as described above. Loss of endothelial cell
HIF-1a significantly decreases metastatic success
in this assay (Figure 6A). However, loss of HIF-2a
in endothelial cells significantly increases both the
number (Figure 6B) and size (Figure 6C) of pulmo-
nary tumors in this experimental system.
DISCUSSION
The relationship of hypoxia to tumor progression
has been well documented; hypoxia and hypoxia-
associated necrosis have also been repeatedly
linked to metastasis (De Jaeger et al., 1998). It is
likely that hypoxic response is an intrinsic part of
almost every stage of metastasis, through bothhypoxia-induced tumor cell motility and increased vascular/
endothelial permeability (Erler and Giaccia, 2006; Rofstad and
Danielsen, 1999; Weis et al., 2004).
Clearly, a key to movement of tumor cells during hematoge-
nous metastasis is transposition across endothelial barriers;
the question being the degree to which this is influenced byll 21, 52–65, January 17, 2012 ª2012 Elsevier Inc. 57
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Figure 4. Inhibition of VEGF Expression upon iNOS Inhibition Is A Phenomenon Specific to Endothelial Cells
(A) Quantitative PCR of wild-type mouse endothelial cells (mEC), human umbilical vascular endothelial cells (hUVEC), mouse embryonic fibroblasts (MEF), and
Lewis lung cancer cells (LLC) exposed to normoxia or hypoxia (21% or 1%O2, respectively) in the presence or absence of 15 mM1400W, to assess mRNA levels
of VEGF and PGK (hypoxia and HIF-1a control). Data is average ± SEM of ratio of mRNA levels in sample compared to mRNA levels in WT untreated during
normoxia.
(B) Quantitative PCR of RNA extracted from subcutaneous LLCGFP tumors in WT mice. Mice were treated with two intraperitoneal injections: the first, a 15 mg/kg
1400W (or respective saline control of equal volume) at 8 hr before sacrifice, and the second, a 10 mg/kg injection at 4 hr prior to sacrifice. An asterisk is placed
above differences with a significance exceeding p < 0.05; **p < 0.01; ***p < 0.001.
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Figure 5. Hypoxia-Induced Tumor Cell
Migration Is Inhibited in the Absence of
Active iNOS
(A) Endothelial monolayers of different genotypes
were incubated with 15 mM of 1400W for 3 hr, and
then washed to remove inhibitor. They were then
incubated with LLC cells (in the absence of inhib-
itor) for 9 hr at either 21% or 1% O2, to assay for
effects of inhibition of iNOS in endothelial cells on
tumor cell migration.
(B) Migration assay using WT and iNOS null EC
monolayers.
(C) Metastases in WT mice lungs 14 days posttail
vein injection of 1 3 106 LLCGFP cells. Experi-
mental mice received a total of two intraperitoneal
injections of either control saline or 1400W, one at
8 hr, and one at 4 hr (the first of 15 mg/kg followed
by 10 mg/kg) immediately prior to tumor cell
injections. In this figure, data presented is
average ± SEM. An asterisk is placed above
differences with a significance exceeding p < 0.05;
**p < 0.01; ***p < 0.001.
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response in the endothelium is controlled to a significant extent
by two transcription factors, HIF-1a and HIF-2a (Liu et al., 2011;
Skuli and Simon, 2009; Tang et al., 2004; Ten and Pinsky, 2002).
These in turn control a number of EC effectors: receptors and
signal transduction molecules that shape endothelial and
vascular behavior. One of the most potent and wide-ranging of
these is NO. In the work described here, it is clear that NO levels
are modified in EC by hypoxia in a manner that is controlledCancer Cell 21, 52–6differentially by the HIF isoforms. Surpris-
ingly, we also show that this control in
turn correlates with either suppression
or enhancement of metastasis.
A number of studies have shown that
HIF-1a is a powerful regulator of the
NOS2, or iNOS gene (Melillo et al., 1997;
Ortiz-Masia´ et al., 2010; Tafani et al.,
2010; Zhou et al., 2009). Hypoxia acts in
many cell types to induce iNOS, and
thus to increase NO levels via the action
of the synthase. It was recently shown
that macrophages regulate NO homeo-
stasis in part through Th1 cytokine
stimulation and induction of HIF-1a
transcriptionally; this in turn activates
iNOS expression and ultimately increases
NO production (Doedens et al., 2010).
It has also been recently shown that
HIF-2a induces ARG1 expression
following Th2 cytokine stimulation in
macrophages (Takeda et al., 2010). The
combined actions of the twoHIF-a factors
can thus regulate NO homeostasis
(Takeda et al., 2010). The present study
demonstrates that this differential and
antagonistic action of the two HIF-a
factors is not limited to cytokine-inducedresponses in macrophages: loss of HIF-1a limits iNOS expres-
sion in EC, and thus restricts NO production, and loss of
HIF-2a results in lower levels of ARG1, and increased NO
production.
NO levels have well-documented effects on EC function.
Substantial literature exists describing the roles of NO in EC,
both from extrinsic sources and intrinsic ones (Fukumura et al.,
2006; Mark et al., 2004; Ziche and Morbidelli, 2009). However,
endothelial-derived NO was previously thought to be primarily5, January 17, 2012 ª2012 Elsevier Inc. 59
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Figure 6. Endothelium-Specific Deletions of
HIF-1a and HIF-2a Have Opposing Effects
on Tumor Metastases
LLCGFP cells (1 3 106) were injected via tail vein
into HIF-1adf/Tie2Cre or HIF-2adf/Tie2Cre mice.
All Cre-expressing and WT mice were lethally
irradiated, and then received WT bone marrow, in
order to ensure endothelial-exclusive deletion of
gene of interest. Lungs were collected 14 days
postinjection, fixed, and sectioned for hematoxylin
and eosin staining.
(A) Representative images of mouse lungs 14 days
post-LLCGFP tail vein injection. Scale bars repre-
sent 5 mm.
(B) Number of metastases foci found in lungs of
HIF-1a null, HIF-2a null, and their respective WT
(i.e., df = double floxed/cre negative) controls.
(C) Average of relative tumor area in lung sections
obtained by quantifying tumor area versus whole
lung area in every third section of whole lungs. In
this figure, data presented is average ± SEM. An
asterisk is placed above differences with a signifi-
cance exceeding p < 0.05; **p < 0.01; ***p < 0.001.
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HIF Isoforms in Endothelium during Metastasisdue to NO production through the eNOS enzyme (Fukumura
et al., 2001); it is clear from the results described here that
iNOS is a key source of NO in a hypoxic EC.
We also show here that iNOS itself is a key regulator of
VEGF-A expression in endothelium, and that in its absence,
fundamental aspects of VEGF-A function are disturbed,
including VEGFR2 activation and tube formation. Although
a number of workers have shown that iNOS is important for
metastasis and can be linked to VEGF-A expression (Davie
et al., 2007; Hosogi et al., 2005; Van der Wall and Palmer,
2006), the demonstration that it has an endothelial-specific role
in those processes represents an intriguing avenue for tissue-
specific VEGF-A inhibition.
One recent study showed that NO could act as an inhibitor
of the prolyl hydroxylases, which in turn would act to increase
HIF isoform stability and expression, and that this can act
by interceding in the feedback loop where HIF isoforms
themselves induce the expression of prolyl hydroxylases
(Berchner-Pfannschmidt et al., 2007). Loss of iNOS would
thus lead to increased degradation of HIF isoforms via
increased activity of the prolyl hydroxylases; current work is
underway to determine the role of this feedback loop in EC
hypoxic response.
It is shown here that in EC, there are specific and opposing
roles for the two HIF isoforms in regulating NO. Previously
published studies of HIF-2a loss in EC either did not examine
metastasis (Yamashita et al., 2008), or only scored animals
qualitatively as metastatic or not after xenografts, i.e., did not
count metastases or overall metastatic tumor burden (Skuli60 Cancer Cell 21, 52–65, January 17, 2012 ª2012 Elsevier Inc.et al., 2009). It is clear that quantitative
metastatic success is differentially influ-
enced by the two HIF isoforms in ECs.
Interestingly, deletion of prolyl hydrox-
ylase activity has profound effects on
overall vessel maturation and pericyte
coverage, in turn affecting vessel perme-ability and function (Coulon et al., 2010; Mazzone et al., 2009;
Schneider et al., 2010). As decreased or altered hydroxylation
will affect availability and activity of both HIF isoforms, under-
standing the relationships between individual hydroxylases and
individual HIF isoforms will be an essential parameter to
completely understand, in order to ultimately predict the
effect of pharmacological hydroxylase inhibitors on tumor pro-
gression and metastasis.
It should also be noted that we have demonstrated an impor-
tant difference in the roles of HIF isoforms in regulating tumor
progression, as shown in the model in Figure 7. The model
indicates the differential effects of the HIF isoforms in endo-
thelial cells: here, in a thrombotic focus of tumor cells clogging
a tissue capillary. This vascular blockage would immediately
cause localized drops in oxygen tension in both the tumor cells
and surrounding stroma, including the local endothelial cells.
Depending on how the thrombus resolves, the HIF isoforms in
the endothelium could act to regulate NO homeostasis locally,
and in turn affect metastatic success.
The homeostatic regulation of NO clearly depends on differen-
tial expression of HIF-1 and HIF-2; this expression may be regu-
lated by temporal differences in the isoforms’ response to
hypoxia (Holmquist-Mengelbier et al., 2006), and/or by differing
cytokine/growth factor responsiveness (Takeda et al., 2010) as
well as other factors in the tumorigenic milieu. This model rein-
forces the still developing concept that these two HIF isoforms
can act antagonistically, and not redundantly, to regulate bio-
logical processes in malignancy (Bertout et al., 2009; Gordan
et al., 2007; Roberts et al., 2009).
HIF-1 -/- EC HIF-2 -/- EC 
Metastatic success 
Hypoxic EC 
Figure 7. Differential Functions of HIF-1 and HIF-2 during Metastasis Depend on Differential NO Synthesis
As shown, HIF-1 and HIF-2 response in endothelial cells gives rise to differing levels of NO production following hypoxic induction of the factors: in this case,
through hypoxic stress caused by tumor cell-induced blockage of a capillary. This, in turn, results in differing levels of metastatic success when one or the other
HIF is genetically deleted from the endothelial cell. A remaining and important question is how hypoxic stress can cause differing levels of induction of the twoHIF
factors.
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in the context of VHL deletion, HIF-2a can act as the driver for
malignant cell progression and tumor angiogenesis (Haase,
2006; Kondo et al., 2002; Smith et al., 2005). The data presented
here indicate that the tumor stroma and malignant cells likely
employ HIF isoforms differently, and as pharmacological
manipulation of HIF factors is evaluated, their impact on HIF
isoforms at a tissue-specific level should thus be considered
and evaluated.
EXPERIMENTAL PROCEDURES
Animal Experiments
All animal studies were carried out according to the animal protocol approved
by the UCSD Institutional Animal Care and Use Committee. Mice were main-
tained on a standard chow in a pathogen-free animal facility with 12 hr light
and dark cycles.
Deletion ofHIF-1a orHIF-2a in EC andmyeloid cells was obtained by crossing
HIF-1adf or HIF-2adf females (generated as previously described [Ryan et al.,
1998 and Gruber et al., 2007, respectively]) to HIF-1adf/Tie2Cre+ or HIF-2adf/
Tie2Cre+ males. Cre+ and Cre females between 3 and 4 weeks of age were
lethally irradiated (1,000 Rad) and received wild-type bone marrow (1 3 106
bone marrow [BM] cells per mouse) to restore genotype of hematopoietic cells
and generate endothelial cell null mice and comparable df/wild-type controls.
Tie2-specific deletion of HIF-1a in polyoma middle T (PyMT) tumor model
was obtained by crossing HIF-1adf females with HIF-1adf/Tie2-Cre+/PyMT+males. Only virgin females were used in this study. After weaning at 3 weeks
of age, mice were palpated once per week. Tumor onset age was when
a 2 3 2 mm palpable solid mass appeared. Tumors were measured in two
dimensions using digital calipers. Mice were sacrificed when any tumor had
reached 1 3 1 cm (endpoint).
C57Bl/6 WT and iNOS-deficient mice in the C57Bl/6 background were
purchased from the Jackson Laboratory (Bar Harbor, ME) and used to purify
endothelial cells lacking iNOS.
Histology and Immunohistochemistry
Lung and tumor tissues were fixed in 10%phosphate-buffered formalin (Fisher
Scientific) for 16 hr and embedded in paraffin. Lung metastases were counted
in hematoxylin and eosin (H&E) stained sections as previously described
(Liao et al., 2007). Blood vessels in tumors were detected using rat anti-mouse
CD34 antibody (1:100 dilution, NB600-1071, Novus). Secondary antibody for
CD34 staining is biotinylated goat anti-rat IgG (1:200 dilution, sc-2041, Santa
Cruz Biotechnology). Staining was revealed using Vectastain ABC kit (Vector
Laboratories). Microvessel density was quantified using a Chalkley graticule
eyepiece.
Generation of LLCGFP Cells
Lewis lung carcinoma cells were infected with a lentivirus expressing GFP
(made available by Dr. Cornelis Murre, University of California, San Diego) ac-
cording to the standard protocol for retrovirus infection. Single clones from
FACS-sorted GFP-positive cells were selected, and the clone used in this
showing the highest GFP expression was used. LLCGFP cells were cultured
in DMEM (11965-092, Invitrogen) supplemented with 10% fetal bovineCancer Cell 21, 52–65, January 17, 2012 ª2012 Elsevier Inc. 61
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HIF Isoforms in Endothelium during Metastasisserum (26140-079, Invitrogen), 100 U ml1 penicillin, and 100mg ml1
streptomycin.
Tumor Cell Extravasation
A total of 13 106 LLCGFP cells in 200 ml sterile PBS were injected intravenously
into bone marrow-reconstituted WT and HIF-1a and HIF-2a EC null mice.
Lungs were excised 14 days postinjection and fixed in 10% formalin for
histological analysis. The number of tumors were counted in H&E stained
10 mm serial lung sections of the whole lungs and compared between WT
and EC null mice. The area of each lung tumor of every third section was
measured and compared to the whole lung area in the section for an assess-
ment of tumor burden, using ImageJ software.
Tumor Cell Intravasation
Right mammary gland pad 4 was surgically cleared in 3–4-week-old HIF-1adf
and HIF-1adf/Tie2-Cre+ female mice. Removal of ductal tree was confirmed
by carmine whole-mount staining. Two months after surgery, bone marrow
reconstitution was performed on these mice to obtain WT and EC null mice
with cleared fat pads. Six weeks post-BM transplantation, 2.5 3 106 LLCGFP
cells in 50 ml sterile PBS were implanted into the cleared mammary gland.
Mice were sacrificed 21 days later, and tumors were weighed, lungs removed
and fixed for histological analysis of metastasis, and blood was collected
by cardiac puncture. Relative abundance of genomic GFP in blood was
determined by quantitative PCR to assess the presence of circulating tumor
cells.
Quantitative Real-Time PCR
Genomic DNA was isolated using DNeasy Blood and Tissue Kit (QIAGEN).
GFPDNAwas quantified using an ABI Prism 7700 Sequence Detector (Applied
Biosystems) and normalized to VEGF DNA levels. Conditions for the PCR: one
10-min incubation at 95C, followed by 40 cycles of 15 s at 95C and 1 min at
60C. Primers used in this study include:
GFP forward, 50-GGAGCGCACCATCTTCTTCA-30;
GFP reverse, 50-AGGGTGTCGCCCTCGAA-30;
VEGF forward, 50-CTATGGAGGCCAGAAGAGGGTAT-30;
VEGF reverse, 50-CCCACATCAGGTGGCTCATAA-30; and
VEGF probe, 50-(6FAM)AGATCCCTTGAAGCTAG(MGBNFQ)-30.
For quantitative analysis of steady-state mRNA levels, total RNA was
extracted from normoxia- and hypoxia-treated cells, using UltraClean Tissue
and Cells RNA Isolation Kit (MoBio). cDNA was synthesized from 1 mg of
total RNA, using Superscript III (Invitrogen) according to the manufacturer’s
instructions. Relative abundance of transcripts of interest was assessed by
Q-PCR following normalization to b-ACTIN transcript levels. Primer pair and
primer/probe sets used were as follows:
mb-actin forward, 50-AGGCCCAGAGCAAGAGAGG-30;
mb-actin reverse, 50-TACATGGCTGGGGTGTTGAA-30.
mVEGF total forward, 50-ATCCGCATGATCTGCATGG-30;
mVEGF total reverse, 50-AGTCCCATGAAGTGATCAAGTTCA-30;
mVEGF probe, 50-[6FAM]-TGCCCACGTCAGAGAGCAACATCAC-
[BHQ1a-Q]-30.
mPGK forward, 50-CAAATTTGATGAGAATGCCAAGACT-30;
mPGK reverse, 50-TTCTTGCTGCTCTCAGTACCACA-30;
mPGK probe, 50-[6FAM]-TATACCTGCTGGCTGGATGGGCTTGGACT-
[BHQ1a-Q]-30;
mArginase forward, 50- AACACGGCAGTGGCTTTAACC-30 (Takeda et al.,
2010);
mArginase reverse, 50 GGTTTTCATGTGGCGCATTC-30 (Takeda et al.,
2010);
miNOS: TaqMan Gene Expression Assay Mm00440488_m1 (Applied
Biosystems); and
hiNOS: TaqMan Gene Expression Assay Hs01075521_m1 (Applied
Biosystems).
Data are presented as average ± SEM of fold-change (ratio) between each
sample and the WT normoxic control.62 Cancer Cell 21, 52–65, January 17, 2012 ª2012 Elsevier Inc.Isolation of Primary Endothelial Cells
Primary endothelial cells were isolated and cultured from lungs of HIF-1adf,
HIF-2adf, VEGFdf, or iNOS null mice, as previously described (Dong et al.,
1997; Tang et al., 2004) with the following modifications: the lungs were
excised, minced, and digested for 90 min at 37C in 2 mg/ml collagenase
type I (Roche) in HBSS containing 2 mM CaCl2, 2 mM MgSO4, and 20 mM
HEPES. The digest was filtered through a 70 mmnylon cell strainer andwashed
once in HBSS. Pellet was then resuspended in PBS containing 0.1% BSA and
incubated with anti-CD31-coated magnetic beads (Dynal, Invitrogen) for 1 hr
at 4C. Cells and beads were plated in endothelial cell growth medium
(ECGM) consisting of low glucose DMEM:F12 with 1%penicillin/streptomycin,
1% nonessential aminoacids, 2 mM sodium pyruvate, buffered with 20 mM
HEPES and containing 20% FBS (Omega Scientific, Tarzana, CA), 20 mg/ml
Heparin (Sigma, St. Louis, MO), and 75 mg/ml endothelial mitogens (Biomed-
ical Technologies). Cell identity and culture purity were confirmed by immuno-
detection with anti-VE-cadherin (Santa Cruz Biotechnology, sc-6458), and
LDL uptake.
Transendothelial Cell Migration Assay
After 12–14days,cells fromdouble-floxedgenotypes, in theoriginal isolates (p0)
were infectedwith adenovirus expressingCre recombinase (forHIF-1a,HIF-2a,
orVEGFdeletion) or adenovirus expressingb-gal, for controlWTcells. Allmigra-
tion experiments shown were performed using endothelial cell monolayers
generated from P1 or P2 cells. Endothelial cells (5 3 105) were seeded into
COSTAR transwells (6.5mmdiameter, pore size 8 mm;Corning, NY) grown until
confluent. Migration of tumor cells was examined by seeding 5 3 105 LLCGFP
cells onto the endothelial monolayer and the inserts incubated for 9 hr under
21% (kept in normoxic growth incubator) or 1% oxygen (transferred to hypoxic
incubator), withmedia on both upper and lower chambers. Inserts were stained
with0.1%crystal violet in 10%ethanol andmountedontoglass slides.Migrated
cells were counted in five random fields per insert at 1003 magnification.
Average was calculated from a minimum of three inserts per treatment. Data
is expressed as average ± SEM of the ratio between migrated cells observed
through each endothelial genotype and/or treatment and the migration
observed through the WT endothelium under normoxic conditions.
Effect of iNOS inhibition in endothelial cells on tumor cell migration was
done by preincubation of endothelial monolayer with 15 mM of 1400W for
3 hr prior to the migration experiment (normoxia and hypoxia for 9 hr), which
occurred in the absence of the inhibitor.
Immunoprecipitation of VEGFR2
Subconfluent (80%) EC cultures in 6-well plate wells were incubated at 21%
(normoxia) or 1% (hypoxia) for 9 hr, rinsed briefly with cold PBS, and immedi-
ately frozen in liquid N2. Cells were lysed in RIPA buffer (Cell Signaling, 9806S)
containing protease inhibitors (Minitab, Roche), and 100 mM PMSF. Protein
was quantified in clarified lysates and equal amounts were used for pull
down of VEGFR2 (Santa Cruz Biotechnologies, sc-504). Whole cell lysate
and primary antibody were preincubated O/N in a final volume of 750 mL, at
4C. Protein A/G Plus Agarose beads (Santa Cruz Biotechnologies, sc-2003)
were added and incubated O/N with end-over-end tumbling at 4C. A/G
beads were washed and bound protein resolved by SDS-polyacrylamide gel
electrophoresis, and transferred to PVDF membrane for immunoblotting with
anti-VEGFR2 (sc-504) and antiphosphotyrosine antibody (4G10 Platinum,
Millipore) to detect and quantify the activated form of VEGFR2.
Immunoblotting
Equal amounts of protein (15 mg) for normoxia- and hypoxia-treated cells were
loaded onto 3%–8% acrylamide Tris-Glycine gels (Invitrogen) and transferred
to PVDF membrane (Millipore), according to established western blotting
procedures. Primary antibodies were used at 1:1,000 dilutions unless other-
wise stated (iNOS [sc-651], eNOS [BD 610296], HIF-1a [Novus Biologicals
NB-100-049], HIF-2a [R&D AF2997]). Proteins of interest were detected
following secondary incubation with HRP-conjugated antibodies and ECL
Plus chemiluminescence detection kit (Amersham).
NO Measurements
Endothelial cells were grown to confluence and incubated for 48 hr at 21% or
0.5% O2 in growth media. Nitrate and nitrite levels were quantified in
Cancer Cell
HIF Isoforms in Endothelium during Metastasisconditionedmedia using Sievers Nitric Oxide Analyzer (NOA 280i) according to
the manufacturer’s instructions. EC production of NO during normoxia and
hypoxia was quantified by measuring the nitrites in the growth medium, which
is likely an underestimation of the NO produced. Because the EC growth
medium is saturated with nitrates, the contribution of EC production of NO
to this pool was undetectable.
Statistical Analyses
Statistical analysis in all cases (Q-PCR, NO levels, migration assays) was
done using unpaired Student’s t test, where values observed for each sample
were routinely compared to the ones found in wild-type controls under
normoxic/untreated conditions. Data are expressed as mean ± SEM unless
otherwise stated.
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